BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 15313926)

  • 1. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
    Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA
    Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction.
    Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA
    Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z; Zhang M; Goldman CK; Ravetch JV; Waldmann TA
    Cancer Res; 2003 Oct; 63(19):6453-7. PubMed ID: 14559836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo.
    Ito A; Ishida T; Utsunomiya A; Sato F; Mori F; Yano H; Inagaki A; Suzuki S; Takino H; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    J Immunol; 2009 Oct; 183(7):4782-91. PubMed ID: 19748990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
    Zhang Z; Zhang M; Garmestani K; Talanov VS; Plascjak PS; Beck B; Goldman C; Brechbiel MW; Waldmann TA
    Blood; 2006 Aug; 108(3):1007-12. PubMed ID: 16569769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
    Carlo-Stella C; Di Nicola M; Turco MC; Cleris L; Lavazza C; Longoni P; Milanesi M; Magni M; Ammirante M; Leone A; Nagy Z; Gioffrè WR; Formelli F; Gianni AM
    Cancer Res; 2006 Feb; 66(3):1799-808. PubMed ID: 16452241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
    Chen J; Zhang M; Ju W; Waldmann TA
    Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
    Dialynas DP; Shao L; Billman GF; Yu J
    Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
    Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
    Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
    Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
    Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient engraftment of primary adult T-cell leukemia cells in newborn NOD/SCID/beta2-microglobulin(null) mice.
    Kawano N; Ishikawa F; Shimoda K; Yasukawa M; Nagafuji K; Miyamoto T; Baba E; Tanaka T; Yamasaki S; Gondo H; Otsuka T; Ohshima K; Shultz LD; Akashi K; Harada M
    Leukemia; 2005 Aug; 19(8):1384-90. PubMed ID: 15959532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous Tax-specific CTL therapy in a primary adult T cell leukemia/lymphoma cell-bearing NOD/Shi-scid, IL-2Rγnull mouse model.
    Masaki A; Ishida T; Suzuki S; Ito A; Mori F; Sato F; Narita T; Yamada T; Ri M; Kusumoto S; Komatsu H; Tanaka Y; Niimi A; Inagaki H; Iida S; Ueda R
    J Immunol; 2013 Jul; 191(1):135-44. PubMed ID: 23733874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
    Zhang M; Zhang Z; Goldman CK; Janik J; Waldmann TA
    Blood; 2005 Feb; 105(3):1231-6. PubMed ID: 15383455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.
    Ito A; Ishida T; Yano H; Inagaki A; Suzuki S; Sato F; Takino H; Mori F; Ri M; Kusumoto S; Komatsu H; Iida S; Inagaki H; Ueda R
    Cancer Immunol Immunother; 2009 Aug; 58(8):1195-206. PubMed ID: 19048251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
    Zhang M; Yao Z; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Janik J; Brechbiel MW; Waldmann TA
    Blood; 2006 Jul; 108(2):705-10. PubMed ID: 16551968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
    Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.